Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19
Open accessAbstract
Lung epithelial and endothelial cell damage and defective lung tissue repair contribute to fatal COVID-19.
AI snapshot
Written from the paper’s full text.
TL;DR
Lung autopsy and antemortem plasma analyses from 18 fatal COVID-19 cases show progressive diffuse alveolar damage, alveolar-capillary barrier injury, defective lung repair, impaired fibrinolysis, and epithelial/endothelial cellular senescence. These findings outline a temporal framework linking viral load, thrombosis, fibrosis, and age-related risk pathways in fatal SARS-CoV-2 infection.
Key findings
- In 18 fatal COVID-19 autopsy cases (mean age 67.7 years; range 39–101; 10 males, 8 females; symptom onset-to-death 3–47 days), all lungs showed diffuse alveolar damage (DAD), with acute DAD predominant at short symptom onset-to-death and fibrotic DAD at longer durations.
- Alveolar-capillary barrier damage included reduced surfactant protein expression, loss of AT2/AT1 and basal epithelial cells, decreased E-cadherin, claudin-5, and collagen type 4, plus impaired repair markers such as decreased FGFR2, SOX2, ITGA6, FGF2, and stem cell factor.
- Thrombosis and impaired fibrinolysis were prominent: increased lung/plasma PAI-1, VWF, tissue factor, and fibrin, with decreased plasma ADAMTS13; PAI-1 localized to unresolved clots and PAI-1–positive neutrophils.
- Cellular senescence markers were modulated in lung epithelium and endothelium, including increased nuclear p21, γH2A.X, CDKN2A/CDKN1A, and decreased sirtuin-1; correlations included acute DAD with viral load (R = 0.565, P = 0.024), fibrotic DAD with age (R = 0.565, P = 0.015), fibrotic DAD with SOTD (R = 0.555, P = 0.017), and SOTD with viral load (R = −0.722, P = 0.001).
Methods
- Case series of postmortem FFPE lung autopsy samples from 18 patients with fatal SARS-CoV-2 infection (March–July 2020) and antemortem plasma from 6 of these cases (11 samples total); normal control FFPE lung tissue from 10 individuals without COVID-19 and plasma from 10 healthy volunteers were used for comparisons.
- Analyses included histology, immunohistochemistry, immunofluorescence, qRT-PCR for SARS-CoV-2 RNA, next-generation sequencing for viral genomes and host SNPs, Agilent whole-genome microarray expression profiling, and multiplex plasma protein measurements using Olink and Luminex platforms.
- Statistical methods included Pearson correlation, Student’s t test, principal component analysis, Benjamini-Hochberg correction for multiple comparisons, and Ingenuity pathway analysis for gene ontology enrichment.
Limitations
- The paper states that the overall number of patients was small and that larger autopsy studies are needed to examine demographics, comorbidities, and in-hospital interventions such as mechanical ventilation.
- The paper notes uncertainty about whether the available lung specimens used for imaging and transcriptomic analyses were representative of the whole lung.
- The paper states that because all cases were fatal, it is unknown to what extent these pathological processes occur in mild-to-moderate, hospitalized nonfatal, or long-term sequelae cases; the text also makes evident that the plasma subset was only 6 patients, limiting analysis of clinical variables.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 64 cited sources checked · 0 supported · 0 flagged
- Findingown data
Transcripts associated with the reactive oxygen species response were modulated in lung tissue.
“Transcripts associated with the reactive oxygen species (ROS) response were also modulated in lung tissue (Fig. 3D).”
Quote in the paperNot a substantial claim - Findingown data
Plasma concentrations of IFNLR1, DDX58, and leukemia inhibitory factor were significantly elevated in patients with COVID-19 compared to normal healthy volunteers.
“Multiplex measurements of immune response proteins in antemortem plasma samples from patients with COVID-19 (n = 6 patients sampled up to four times before death; n = 11 samples total) demonstrated that concentrations of IFN-related proteins IFNLR1, DDX58, and leukemia inhibitory factor were significantly (P < 0.05) elevated compared to normal healthy volunteers (n = 10) (fig. S8B).”
Quote in the paperNot a substantial claim - Findingown data
FGFR2 and SOX2 transcripts were decreased in lung tissue from patients with COVID-19.
“However, FGFR2 and SOX2 transcripts were decreased, as were transcripts of other genes involved in stem cell renewal and differentiation (BMP4 and BMPR1A) (30).”
Quote in the paperSubstantial claim - Findingown data
Postmortem lung sections from all 18 cases showed DAD as the predominant histopathologic finding, ranging from acute DAD through organizing and late fibrotic DAD.
“The postmortem lung sections from all 18 cases showed DAD as the predominant histopathologic finding, ranging from acute DAD through organizing and late (fibrotic)–stage DAD (fig. S3 and table S11).”
Quote in the paperSubstantial claim- Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
- Findingown data
Cases with longer illness duration displayed a pattern of multiple colocalized fibrin and tissue factor patches or fibrin balls in alveolar spaces that also expressed Col 1 but not αSMA.
“The first pattern featured multiple colocalized fibrin and tissue factor patches or fibrin “balls” in alveolar spaces that also expressed Col 1 but not αSMA (Fig. 3B).”
Quote in the paperNot a substantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
Pulmonary vascular remodeling with excessive vessel wall-associated αSMA and Col 1 expression was prominent in intermediate and long-duration cases.
“Pulmonary vascular remodeling with excessive vessel wall–associated αSMA and Col 1 expression was another prominent finding in intermediate and long-duration cases (fig. S13).”
Quote in the paperNot a substantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
There was a negative correlation between symptom onset-to-death time and SARS-CoV-2 RNA viral load (R = −0.722, P = 0.001).
“and SOTD with SARS-CoV-2 RNA viral load (R = −0.722, P = 0.001).”
Quote in the paperNot a substantial claim - Findingown data
Gene ontology analysis of transcripts increased in longer duration cases revealed enrichment of processes linked to fibrosis and wound repair, including fibrosis signaling, epithelial-mesenchymal transition, Wnt and stem cell-related signaling, adipogenesis, and macrophage, fibroblast, and endothelial cell function.
“Gene ontology analysis of transcripts with increased expression in longer duration cases revealed enrichment of processes linked to fibrosis and wound repair, including fibrosis signaling, epithelial-mesenchymal transition, Wnt and stem cell–related signaling, adipogenesis, as well as macrophage, fibroblast, and endothelial cell function (Fig. 4A).”
Quote in the paperSubstantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
Acute DAD was characterized by marked deposition and colocalization of intra-alveolar fibrin and tissue factor in hyaline membranes.
“Acute DAD was characterized by marked deposition and colocalization of intra-alveolar fibrin and tissue factor in hyaline membranes (Fig. 3A and fig. S3, A to D).”
Quote in the paperSubstantial claim - Findingown data
There was a positive correlation between acute DAD and SARS-CoV-2 viral RNA load (R = 0.565, P = 0.024).
“a positive correlation was calculated between acute DAD and SARS-CoV-2 viral RNA load [correlation coefficient (R) = 0.565, P = 0.024]”
Quote in the paperNot a substantial claim - Findingown data
In cases with short SOTD, high viral antigen deposition was identified in AT1 and AT2 cells, bronchiolar epithelial cells including respiratory epithelial basal cells, and less frequently in vascular endothelial cells and adjacent pericytes.
“In cases with a short SOTD, high viral antigen deposition was identified by immunohistochemistry in AT1 and AT2 cells, bronchiolar epithelial cells (including respiratory epithelial basal cells) (Fig. 1B), and, less frequently, in the cytoplasm of vascular endothelial cells and adjacent pericytes of medium and small blood vessels in cases with the highest viral load (Fig. 1C and fig. S5).”
Quote in the paperSubstantial claim- Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
- Findingown data
Plasma proteins associated with neutrophil and ROS responses, including IL8, CXCL10, EN-RAGE, IL6, and PRDX1, were elevated in lung tissue from patients with COVID-19.
“Plasma proteins associated with neutrophil and ROS responses including IL8, CXCL10, and EN-RAGE primarily derived from activated neutrophils (37), IL6, and PRDX1 were also elevated in lung tissue from patients with COVID-19 (Fig. 3E).”
Quote in the paperSubstantial claim - Findingown data
A subset of neutrophils showed increased nuclear expression of citrullinated histone H3, an early indicator of neutrophil extracellular trap formation.
“A subset of neutrophils showed increased nuclear expression of citrullinated histone H3 (CitH3), an early indicator of neutrophil extracellular trap (NET) formation (fig. S15A).”
Quote in the paperNot a substantial claim - Findingown data
Expression of genes encoding type I and III interferons and other interferon signaling transcripts was increased in lung tissue from patients with COVID-19 compared to normal healthy control lung tissue.
“Expression of genes encoding type I and III IFNs, including IFNA4, IFNA5, IFNA10, IFNA21, IL28, and IL29, and other transcripts associated with IFN signaling was increased in lung tissue from patients with COVID-19 compared to normal healthy control lung tissue (fig. S8A).”
Quote in the paperNot a substantial claim - Findingown data
Lung tissue from patients with COVID-19 showed severely diminished and discontinuous claudin-5 and Col IV immunoreactivity.
“In contrast, lung tissue from patients with COVID-19 showed severely diminished and discontinuous claudin-5 and Col IV immunoreactivity.”
Quote in the paperSubstantial claim - Findingown data
Differential expression of genes associated with neutrophil infiltration and activation was observed in lung tissue.
“Consistent with this neutrophil response, differential expression of genes associated with neutrophil infiltration and activation was observed in lung tissue (fig. S16).”
Quote in the paperNot a substantial claim - Findingown data
There was a positive correlation between fibrotic DAD and symptom onset-to-death time (R = 0.555, P = 0.017).
“and fibrotic DAD with SOTD (R = 0.555, P = 0.017).”
Quote in the paperNot a substantial claim - Findingown data
Cases with longer illness duration displayed a pattern of diffuse interstitial fibrosis with marked expression and colocalization of αSMA and Col 1.
“The second pattern featured diffuse interstitial fibrosis with marked expression and colocalization of αSMA and Col 1 (Fig. 3B).”
Quote in the paperSubstantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
Prominent CD163-positive macrophage accumulation was identified in cases with extensive fibrotic DAD compared to lower CD163 expression in normal lungs and acute DAD cases.
“Immunofluorescence analyses identified prominent CD163-positive macrophage accumulation in cases with extensive fibrotic DAD compared to lower CD163 expression in normal lungs and acute DAD cases (Fig. 4C and fig. S19).”
Quote in the paperSubstantial claim - Findingown data
BMP4 and BMPR1A transcripts were decreased in lung tissue from patients with COVID-19.
“However, FGFR2 and SOX2 transcripts were decreased, as were transcripts of other genes involved in stem cell renewal and differentiation (BMP4 and BMPR1A) (30).”
Quote in the paperSubstantial claim - Findingown data
There was a negative correlation between acute DAD and fibrotic DAD (R = −0.76, P = 0.00026).
“A negative correlation was calculated between acute DAD and fibrotic DAD (R = −0.76, P = 0.00026)”
Quote in the paperNot a substantial claim - Findingown data
Plasma concentrations of FGF2 and stem cell factor were decreased in patients with COVID-19.
“Plasma concentrations of FGF2 and stem cell factor, required for lung repair (31, 33), were also decreased in patients with COVID-19 (Fig. 1E).”
Quote in the paperSubstantial claim - Findingown data
Prominent SARS-CoV-2 nucleocapsid protein staining was mainly detected in patients with shorter clinical illness (SOTD <10 days).
“Prominent NP staining was mainly detected in patients with shorter clinical illness (SOTD <10 days) (Fig. 1, A and B, and fig. S4).”
Quote in the paperNot a substantial claim- Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
Cases with short SOTDs showed extensive accumulation of MPO-positive neutrophils either trapped in alveolar septal capillaries or extravasated into fibrin-filled alveolar spaces.
“Cases with short SOTDs showed extensive accumulation of MPO-positive neutrophils either trapped in alveolar septal capillaries or extravasated into fibrin-filled alveolar spaces (Fig. 3C and fig. S14).”
Quote in the paperSubstantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
Plasma concentrations of amphiregulin were elevated in patients with COVID-19.
“Plasma concentrations of amphiregulin, an epidermal growth factor produced by damaged epithelial cells that promotes lung repair (34), were elevated in patients with COVID-19 (Fig. 1E).”
Quote in the paperSubstantial claim - Findingown data
Widespread thrombosis was seen in most cases, ranging from medium-sized vessels to capillary microthrombi.
“Widespread thrombosis was seen in most of the cases, ranging from medium-sized vessels to capillary microthrombi (fig. S3, J to L).”
Quote in the paperSubstantial claim- Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
- Findingown data
Expression of NFATc1, THBS1, FGF7, and FGF10 mRNAs was increased in lung tissue from patients with COVID-19.
“Expression of NFATc1, THBS1, FGF7, and FGF10 mRNAs, which are known to activate FGFR2 (31), was increased in lung tissue from patients with COVID-19 (Fig. 1D).”
Quote in the paperSubstantial claim - Findingown data
Gene ontology analysis of transcripts positively correlated with SARS-CoV-2 viral load revealed enrichment for innate immune and antiviral responses, including interferon signaling, IRF activation, JAK/STAT signaling, and pattern recognition receptors.
“Gene ontology analysis of these sequences revealed enrichment for processes related to innate immune responses and antiviral responses, including interferon (IFN) signaling, IFN regulatory factor activation, Janus kinase/signal transducer and activator of transcription signaling, and pattern recognition receptors (Fig. 1F).”
Quote in the paperNot a substantial claim - Findingown data
There was a positive correlation between fibrotic DAD and age (R = 0.565, P = 0.015).
“fibrotic DAD with age (R = 0.565, P = 0.015)”
Quote in the paperNot a substantial claim - Findingown data
Transcripts negatively correlated with viral load were mainly enriched for cellular metabolism, including carbohydrate/lipid metabolism and molecular transport.
“These transcripts with reduced expression were mainly enriched for processes associated with cellular metabolism, including carbohydrate/lipid metabolism and molecular transport (fig. S9B).”
Quote in the paperNot a substantial claim - Findingown data
Released NETs costaining for CitH3, MPO, and cell-free DNA were sporadically detected in damaged lung parenchyma, airway lumens, alveolar spaces, and platelet-rich thrombi.
“Released NETs costaining for CitH3, MPO, and cell-free DNA were sporadically detected in damaged lung parenchyma, airway lumens, alveolar spaces, and platelet-rich thrombi (fig. S15, C to E).”
Quote in the paperNot a substantial claim - Findingown data
Acute DAD was the predominant histopathology in cases with the shortest recorded symptom onset-to-death times (<10 days).
“Acute DAD was the predominant histopathology observed in cases with the shortest recorded SOTDs (<10 days).”
Quote in the paperSubstantial claim- Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
Reduced Pro-SPC and E-cadherin staining was observed in the alveolar septa of lung tissue from patients with COVID-19 relative to normal lungs, particularly in patients with a short SOTD.
“Reduced Pro-SPC and E-cadherin staining was observed in the alveolar septa of lung tissue from patients with COVID-19 relative to normal lungs, particularly in patients with a short SOTD (Fig. 2A and fig. S10, A and B).”
Quote in the paperSubstantial claim - Findingown data
Patients with COVID-19 with higher viral loads tended to have a shorter symptom onset-to-death time.
“Principal component analysis of these transcripts showed that, in general, patients with COVID-19 with higher viral loads tended to have a shorter SOTD (fig. S7), consistent with a previous report (35).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35] Nienhold R, Ciani Y, Koelzer VH, Tzankov A, Haslbauer JD, Menter T, Schwab N, Henkel M, Frank A, Zsikla V, Willi N, Kempf W, Hoyler T, Barbareschi M, Moch H, Tolnay M, Cathomas G, Demichelis F, Junt T, Mertz KD, Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nat. Commun 11, 5086 (2020). 33033248 PMC7546638 source
Not checked in the free run.
- Findingown data
In all evaluated cases, the SARS-CoV-2 strains encoded the Spike D614G mutation.
“In all cases evaluated, the SARS-CoV-2 strains encoded this mutation (table S10).”
Quote in the paperNot a substantial claim- Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
- Findingown data
Processes related to respiratory function, including regulation of surfactant production from AT2 cells, negatively correlated with viral load.
“Processes related to respiratory function also negatively correlated with viral load, including regulation of surfactant production from AT2 cells.”
Quote in the paperNot a substantial claim - Findingown data
All 18 fatal COVID-19 autopsy lung tissues were positive for SARS-CoV-2 by qRT-PCR.
“RNA extracted from formalin-fixed, paraffin-embedded (FFPE) autopsy lung tissues were positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) for SARS-CoV-2 in all 18 cases (Table 1).”
Quote in the paperSubstantial claim- Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
- Findingown data
Marked VWF extravasation into alveolar spaces was observed.
“Marked VWF extravasation into alveolar spaces was also observed, potentially because of alveolar-capillary barrier breakdown (Fig. 5, A to C).”
Quote in the paperSubstantial claim - Findingown data
Endothelial and inflammatory cell expression of IL6 and TGFβ1 in pulmonary blood vessels and alveolar septal capillaries paralleled the localization of PAI-1.
“Endothelial and inflammatory cell expression of IL6 and TGFβ1 in pulmonary blood vessels and alveolar septal capillaries also paralleled the localization of PAI-1 (fig. S22A).”
Quote in the paperSubstantial claim - Findingown data
Expression of SIRT1 mRNA was decreased in COVID-19 lung tissue.
“Expression of SIRT1 mRNA, a major inhibitor of oxidative stress–induced senescence in endothelial and epithelial cells as well as stem cells, was also decreased (Fig. 7F).”
Quote in the paperSubstantial claim - Findingown data
This series of lung autopsy samples from patients with fatal SARS-CoV-2 infection showed a wide range of aberrant pulmonary responses to infection that were associated with viral load, immune response, and duration of clinical illness before death.
“This series of lung autopsy samples from patients with fatal SARS-CoV-2 infection showed a wide range of aberrant pulmonary responses to infection that were associated with viral load, immune response, and duration of clinical illness before death.”
Quote in the paperSubstantial claim - Findingown data
Plasma concentrations of tissue factor and urokinase plasminogen activator were elevated in patients with COVID-19.
“Plasma concentrations of tissue factor, the major activator of the extrinsic coagulation pathway, and urokinase plasminogen activator (uPA), which mediates cleavage of plasminogen to plasmin that then breaks down fibrin clots, were also elevated (Fig. 5E).”
Quote in the paperSubstantial claim - Findingown data
Injured or senescent epithelial and endothelial cells showed elevated nuclear expression of γH2A.X, a marker of ROS-induced DNA damage, in lung tissue from patients with COVID-19.
“Injured or senescent epithelial and endothelial cells also showed elevated nuclear expression of phosphorylated histone H2A.X (γH2A.X), a marker of ROS-induced DNA damage, in lung tissue from patients with COVID-19”
Quote in the paperSubstantial claim - Findingown data
Prominent intravascular and parenchymal VWF immunoreactivity was observed in lung tissue from patients with COVID-19 compared to normal lungs.
“Representative immunofluorescence analyses revealed prominent intravascular and parenchymal VWF immunoreactivity in lung tissue from patients with COVID-19 compared to normal lungs (Fig. 5A and fig. S20, A and B).”
Quote in the paperSubstantial claim - Findingown data
Gene expression analysis revealed increased expression of genes that promote senescence, including SERPINE1 (PAI-1), eNOS3, and the cell cycle inhibitors CDKN2A (p16) and CDKN1A (p21), in COVID-19 lung tissue.
“Gene expression analysis revealed increased expression of genes that promote senescence including SERPINE1 (PAI-1), eNOS3, and the cell cycle inhibitors CDKN2A (p16) and CDKN1A (p21).”
Quote in the paperSubstantial claim - Findingcitation
Decreased plasma concentrations of ADAMTS13 were observed in patients with COVID-19.
“Decreased plasma concentrations of ADAMTS13, the natural metalloprotease inhibitor of VWF, were also observed (Fig. 5E) (38).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [38] Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song WM, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J, Integrin alpha 11 in the regulation of the myofibroblast phenotype: Implications for fibrotic diseases. Exp. Mol. Med 49, e396 (2017). 29147013 PMC5704196 source
Not checked in the free run.
- Findingown data
Expression of genes encoding key inhibitors of fibrinolysis, including SERPINE1, SERPINF1, THBS1, and HRG, was elevated relative to normal lung tissue regardless of clinical illness duration.
“Expression of genes encoding key inhibitors of fibrinolysis, including SERPINE1 [PAI-1 (plasminogen activator inhibitor-1)], SERPINF1 (A2AP), THBS1 (thrombospondin 1), and HRG (histidine-rich glycoprotein) were elevated relative to normal lung tissue regardless of clinical illness duration (Fig. 5D).”
Quote in the paperSubstantial claim - Findingown data
Prominent PAI-1 staining was detected on the endothelium of alveolar septal capillaries and in small- and medium-sized blood vessels containing unresolved clots with tightly packed polyhedrocyte-shaped red blood cells and distinctive entrapped PAI-1-positive cells.
“Prominent PAI-1 staining was also detected on the endothelium of alveolar septal capillaries and in small- and medium-sized blood vessels containing unresolved clots with tightly packed polyhedrocyte-shaped red blood cells and distinctive entrapped PAI-1–positive cells (Fig. 6, A and B).”
Quote in the paperSubstantial claim - Findingown data
The study demonstrated epithelial and endothelial cell senescence in the pathophysiology of COVID-19.
“Our study also demonstrated epithelial and endothelial cell senescence in the pathophysiology of COVID-19, consistent with increased susceptibility and severity of COVID-19 in the elderly and comorbid risk populations.”
Quote in the paperSubstantial claim - Findingown data
Increased nuclear expression of p21 was identified in vascular endothelium and hyperplastic and metaplastic E-cadherin-labeled epithelial cells in lung tissue from patients with COVID-19 compared to normal lungs.
“Immunofluorescence analyses identified increased nuclear expression of the cyclin-dependent kinase inhibitor p21, a marker of senescence, in vascular endothelium and hyperplastic and metaplastic E-cadherin–labeled epithelial cells in lung tissue from patients with COVID-19 compared to endothelial and epithelial cells in normal lungs (Fig. 7, A and B).”
Quote in the paperSubstantial claim - Findingown data
Expression of genes associated with fibrin clot formation (FN1, FGA, and F13A1) was increased in lung tissue from patients with COVID-19.
“Consistent with histological evidence of clot formation with increased staining of VWF and fibrin, expression of genes associated with fibrin clot formation (FN1, FGA, and F13A1) was also increased in lung tissue from patients with COVID-19 (Fig. 5D).”
Quote in the paperSubstantial claim - Findingnone given
Cases with the shortest SOTD showed marked viral antigen deposition in alveolar and bronchiolar epithelial cells, including respiratory epithelial basal cells.
“Cases with the shortest SOTD showed marked viral antigen deposition in alveolar and bronchiolar epithelial cells, including respiratory epithelial basal cells.”
Quote in the paperNot a substantial claim - Findingown data
PAI-1-labeled neutrophils were negative for cleaved caspase 3 and CitH3.
“These PAI-1–labeled neutrophils were also negative for cleaved caspase 3 and CitH3, suggesting a nonapoptotic and non–NET-producing phenotype, respectively (figs. S21 and S15D).”
Quote in the paperSubstantial claim - Findingown data
Colocalized staining of PAI-1 and TGFβ1 was detected in developing fibrotic lesions.
“Colocalized staining of PAI-1 and TGFβ1 was also detected in developing fibrotic lesions (fig. S22, B and C).”
Quote in the paperSubstantial claim - Findingown data
Reduced alveolar septal expression of sirtuin-1 (Sirt-1) was observed in lung tissue from patients with COVID-19.
“Reduced alveolar septal expression of sirtuin-1 (Sirt-1), a nicotinamide adenine dinucleotide–dependent histone deacetylase involved in regulating inflammation, cellular senescence, and stress resistance was also observed (Fig. 7E).”
Quote in the paperSubstantial claim - Findingown data
Elevated nuclear expression of phosphorylated histone H2A.X (γH2A.X), a marker of ROS-induced DNA damage, was observed in lung tissue from patients with COVID-19.
“elevated nuclear expression of phosphorylated histone H2A.X (γH2A.X), a marker of ROS-induced DNA damage, in lung tissue from patients with COVID-19 (Fig. 7D).”
Quote in the paperSubstantial claim - Findingown data
Plasma concentrations of PAI-1 were increased in patients with COVID-19.
“Plasma concentrations of PAI-1 were also increased in patients with COVID-19 (Fig. 5E).”
Quote in the paperSubstantial claim - Findingreasoning
Alveolar damage was accompanied by marked early reduction of pulmonary surfactant expression.
“Alveolar damage was accompanied by the marked early reduction of pulmonary surfactant expression, likely mediated by direct SARS-CoV-2 cytopathic effects on lung AT2 cells.”
Quote in the paperSubstantial claim - Findingown data
Increased nuclear and cytoplasmic p21 expression was observed in αSMA-positive cells, presumably myofibroblasts, located in interstitial fibrotic foci in lungs from COVID-19 cases with longer illness duration.
“Increased nuclear and cytoplasmic p21 expression was also observed in αSMA-positive cells, presumably myofibroblasts, located in interstitial fibrotic foci in lungs from COVID-19 cases with longer illness duration (Fig. 7C).”
Quote in the paperSubstantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
- Findingown data
High PAI-1 immunoreactivity was embedded in large fibrin- and MPO-positive blood clots.
“Immunofluorescence analyses revealed high PAI-1 immunoreactivity embedded in large fibrin- and MPO-positive blood clots (Fig. 6A).”
Quote in the paperSubstantial claim - Findingown data
Cells expressing nuclear p21 showed minimal staining for the proliferation marker Ki67, providing further evidence of a senescence-associated growth arrest phenotype.
“Cells expressing nuclear p21 showed minimal staining for the proliferation marker Ki67, providing further evidence of a senescence-associated growth arrest phenotype (fig. S23).”
Quote in the paperSubstantial claim - Findingown data
Large- and medium-sized thrombi containing intense VWF staining colocalized with CD61-positive platelets, MPO-positive neutrophils, and fibrin.
“Large- and medium-sized thrombi containing intense VWF staining colocalized with CD61-positive platelets, MPO-positive neutrophils, and fibrin (Fig. 5, B and C).”
Quote in the paperSubstantial claim - Findingnone given
Cases with a longer SOTD frequently showed denuded respiratory epithelium and a lack of lung tissue repair and regeneration.
“Cases with a longer SOTD frequently showed denuded respiratory epithelium and a lack of lung tissue repair and regeneration.”
Quote in the paperSubstantial claim - Findingown data
Marked CitH3 staining was observed in platelet-rich thrombi but not in platelet-poor thrombi.
“Marked CitH3 staining was also observed in these platelet-rich thrombi but not in platelet-poor thrombi (fig. S15, D and E).”
Quote in the paperSubstantial claim - Findingown data
SASP markers were elevated at the protein and gene levels in lung tissue from the COVID-19 autopsy case series, including PAI-1.
“SASP markers were elevated at the protein and gene levels in lung tissue from our COVID-19 autopsy case series, including PAI-1, which is considered both a major marker and mediator of cellular senescence (65).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [65] Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK, Plasminogen activator inhibitor-1 is a marker and a mediator of senescence. Arterioscler. Thromb. Vasc. Biol 37, 1446– 1452 (2017). 28572158 PMC5846199 source
Not checked in the free run.
- Findingown data
Increased nuclear p21 expression in hyperplastic and metaplastic epithelial cells as well as endothelial cells was detected in this COVID-19 lung autopsy case series.
“Increased nuclear p21 expression in hyperplastic and metaplastic epithelial cells as well as endothelial cells was detected in this COVID-19 lung autopsy case series.”
Quote in the paperSubstantial claim - Findingown data
PAI-1-positive neutrophils were often identified in clotted vessels in this study.
“PAI-1–positive neutrophils were often identified in clotted vessels in this study, although it is not clear whether this reflected PAI-1 production by neutrophils or binding of plasma PAI-1 to the outer membrane of neutrophils.”
Quote in the paperSubstantial claim - Findingown data
The study observed increased gene and protein expression of several antifibrinolytic factors including PAI-1, the main inhibitor of tissue-type plasminogen activator (tPA) and uPA.
“We also observed increased gene and protein expression of several antifibrinolytic factors including PAI-1, the main inhibitor of tissue-type plasminogen activator (tPA) and uPA.”
Quote in the paperSubstantial claim - Findingown data
Long-duration cases commonly showed vascular remodeling in medium and large vessels.
“Long-duration cases commonly showed vascular remodeling in medium and large vessels.”
Quote in the paperNot a substantial claim - Premisecitation
The major reported lung pathologies of severe COVID-19 include diffuse alveolar damage, organizing pneumonia, and chronic interstitial pneumonia.
“The major reported lung pathologies of severe COVID-19 include diffuse alveolar damage (DAD), organizing pneumonia, and chronic interstitial pneumonia (1–3, 5).”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [1] Batah SS, Fabro AT, Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir. Med 176, 106239 (2021). 33246294 PMC7674971 source
Not checked in the free run.
- cites [2] Bösmüller H, Matter M, Fend F, Tzankov A, The pulmonary pathology of COVID-19. Virchows Arch. 478, 137– 150 (2021). 33604758 PMC7892326 source
Not checked in the free run.
- cites [3] Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J, A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol 33, 2128– 2138 (2020). 32572155 PMC7306927 source
Not checked in the free run.
- cites [5] Sauter JL, Baine MK, Butnor KJ, Buonocore DJ, Chang JC, Jungbluth AA, Szabolcs MJ, Morjaria S, Mount SL, Rekhtman N, Selbs E, Sheng ZM, Xiao Y, Kleiner DE, Pittaluga S, Taubenberger JK, Rapkiewicz AV, Travis WD, Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology 77, 915– 925 (2020). 32614086 PMC7361244 source
Not checked in the free run.
- Study design and conductown data
The small sample size (n = 6 patients) made it difficult to identify potential differences due to the range of clinical illness and sampling time points relative to symptom onset.
“However, the small sample size (n = 6 patients) made it difficult to identify potential differences due to these variables.”
Quote in the paperNot a substantial claim - Interpretationcitation
The decrease in plasma ITGA11 may reflect increased binding of ITGA11 to Col 1 in fibrotic lung tissue.
“ITGA11 selectively binds to Col 1 during fibrogenesis (38); thus, the decrease in plasma ITGA11 may reflect the increased binding of ITGA11 to Col 1 in fibrotic lung tissue.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [38] Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song WM, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J, Integrin alpha 11 in the regulation of the myofibroblast phenotype: Implications for fibrotic diseases. Exp. Mol. Med 49, e396 (2017). 29147013 PMC5704196 source
Not checked in the free run.
- Interpretationown data
Loss of surfactant gene expression is likely the result of viral infection and destruction of AT2 cells.
“Loss of surfactant gene expression is likely the result of viral infection and destruction of AT2 cells.”
Quote in the paperSubstantial claim - Study design and conductnone given
Endothelial cell staining, while suggestive, does not definitively indicate productive viral infection of these cells.
“Endothelial cell staining while suggestive does not definitively indicate productive viral infection of these cells.”
Quote in the paperNot a substantial claim - Interpretationown data
Detection of nucleocapsid protein in airway basal cells suggests that basal cells may be early targets of cytopathic viral infection.
“Detection of NP in airway basal cells, which play key roles in repair and homeostasis of the respiratory epithelium (28), suggests that basal cells may be early targets of cytopathic viral infection.”
Quote in the paperSubstantial claim - Premisecitation
Loss of basal cells precludes regeneration of the airway epithelium, resulting in sustained respiratory compromise.
“Loss of basal cells precludes regeneration of the airway epithelium, resulting in sustained respiratory compromise (41).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [41] Reynolds SD, Giangreco A, Hong KU, McGrath KE, Ortiz LA, Stripp BR, Airway injury in lung disease pathophysiology: selective depletion of airway stem and progenitor cell pools potentiates lung inflammation and alveolar dysfunction. Am. J. Physiol. Lung Cell. Mol. Physiol 287, L1256– L1265 (2004). 15298853 source
Not checked in the free run.
- Interpretationreasoning
Greater staining of CitH3-positive neutrophils in lung tissue from short-duration cases compared to longer-duration cases may indicate a more active contribution of NETs to early pathological processes relative to later disease stages.
“The greater staining of CitH3-positive neutrophils in lung tissue from short-duration cases compared to longer-duration cases may indicate a more active contribution of NETs to early pathological processes relative to later disease stages.”
Quote in the paperNot a substantial claim - Interpretationown data
The data indicate that COVID-19 coagulopathies may be driven by an imbalance in the regulation of prothrombotic and anti-fibrinolytic processes.
“Together, these data indicate that COVID-19 coagulopathies may be driven by an imbalance in the regulation of prothrombotic and anti-fibrinolytic processes.”
Quote in the paperSubstantial claim - Premisecitation
Intra-alveolar neutrophils and injured alveolar epithelial cells are key producers of tissue factor, which directly stimulates fibrin deposition in alveolar spaces, hyaline membranes, and fibrotic foci.
“Intra-alveolar neutrophils and injured alveolar epithelial cells are also key producers of tissue factor, which directly stimulates fibrin deposition in alveolar spaces, hyaline membranes, and fibrotic foci (47, 48).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [47] Bastarache JA, Wang L, Geiser T, Wang Z, Albertine KH, Matthay MA, Ware LB, The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 62, 608– 616 (2007). 17356058 PMC2117249 source
Not checked in the free run.
- cites [48] Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, DeAngelis RA, Lambris JD, Ritis KD, C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J. Immunol 180, 7368– 7375 (2008). 18490736 PMC2673518 source
Not checked in the free run.
- Premisecitation
A spectrum of pulmonary fibrotic disease has been observed in COVID-19 pneumonia from fibrosis associated with organizing pneumonia to severe acute lung injury and widespread fibrosis.
“A spectrum of pulmonary fibrotic disease has been observed in COVID-19 pneumonia from fibrosis associated with organizing pneumonia to severe acute lung injury and widespread fibrosis (52).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [52] Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C, Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect. Dis 20, 425– 434 (2020). 32105637 PMC7159053 source
Not checked in the free run.
- Interpretationown data
VWF extravasation into alveolar spaces was potentially because of alveolar-capillary barrier breakdown.
“Marked VWF extravasation into alveolar spaces was also observed, potentially because of alveolar-capillary barrier breakdown (Fig. 5, A to C).”
Quote in the paperSubstantial claim - Premisecitation
Excessive and persistent damage to alveolar architecture often precedes dysregulated tissue repair processes and fibrosis.
“The observed loss of alveolar basement membrane integrity indicates excessive and persistent damage to the alveolar architecture, which often precedes dysregulated tissue repair processes and fibrosis (16, 17).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [16] Yanagi S, Tsubouchi H, Miura A, Matsumoto N, Nakazato M, Breakdown of epithelial barrier integrity and overdrive activation of alveolar epithelial cells in the pathogenesis of acute respiratory distress syndrome and lung fibrosis. Biomed. Res. Int 2015, 1– 12 (2015). PMC4615219 26523279 source
Not checked in the free run.
- cites [17] Lucas A, Yasa J, Lucas M, Regeneration and repair in the healing lung. Clin. Transl. Immunol 9, e1152 (2020). PMC7338595 32665845 source
Not checked in the free run.
- Premisecitation
Basal cells are stem cells that give rise to ciliated and secretory epithelial cells of the pseudostratified respiratory epithelium.
“basal cells are stem cells that give rise to ciliated and secretory epithelial cells of the pseudostratified respiratory epithelium (40).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [40] Hogan BLM, Barkauskas CE, Chapman HA, Epstein JA, Jain R, Hsia CCW, Niklason L, Calle E, Le A, Randell SH, Rock J, Snitow M, Krummel M, Stripp BR, Vu T, White ES, Whitsett JA, Morrisey EE, Repair and regeneration of the respiratory system: Complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell 15, 123– 138 (2014). 25105578 PMC4212493 source
Not checked in the free run.
- Interpretationown data
These observations suggested a temporal framework for disease progression that outlines a natural history and pathogenesis of SARS-CoV-2 infection.
“these observations nevertheless suggested a temporal framework for disease progression that outlines a natural history and pathogenesis of SARS-CoV-2 infection (fig. S17).”
Quote in the paperSubstantial claim- Rests on an assumption: Pathologic changes likely occurred asynchronously throughout the lung.
- Interpretationreasoning
AT2 cell and surfactant loss may correlate clinically with diminished lung compliance and progressive respiratory failure in severe COVID-19.
“This AT2 cell and surfactant loss may correlate clinically with diminished lung compliance and progressive respiratory failure in severe COVID-19.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Fatal COVID-19 appears to differ from fatal influenza in that direct pulmonary damage due to SARS-CoV-2 infection, and the immune response such damage elicits, is of sufficient severity that it does not require secondary bacterial copathogenesis as seen in influenza.
“Thus, fatal COVID-19 appears to differ from fatal influenza in that direct pulmonary damage due to SARS-CoV-2 infection, and the immune response such damage elicits, is of sufficient severity that it does not require secondary bacterial copathogenesis as seen in influenza.”
Quote in the paperSubstantial claim - Interpretationcitation
Increased TNF and caspase 8 concentrations with minimal evidence of caspase 3-dependent apoptosis suggested a role for inflammatory-driven cell death pathways (e.g., necroptosis).
“Increased TNF and caspase 8 concentrations with minimal evidence of caspase 3–dependent apoptosis suggested a role for inflammatory-driven cell death pathways (e.g., necroptosis), as previously reported (39).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [39] Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, Shen J, Zhou Y, Shi ZL, Zhou P, Peng K, SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct. Target. Ther 5, 235 (2020). 33037188 PMC7545816 source
Not checked in the free run.
- Interpretationown data
Activation of coagulation in fatal COVID-19 appears to coincide with inhibition of fibrinolysis in the lung.
“Activation of coagulation in fatal COVID-19 also appears to coincide with the inhibition of fibrinolysis in the lung.”
Quote in the paperSubstantial claim - Interpretationnone given
The marked early reduction of pulmonary surfactant expression was likely mediated by direct SARS-CoV-2 cytopathic effects on lung AT2 cells.
“Alveolar damage was accompanied by the marked early reduction of pulmonary surfactant expression, likely mediated by direct SARS-CoV-2 cytopathic effects on lung AT2 cells.”
Quote in the paperNot a substantial claim - Interpretationcitation
NETs play a role in intra-alveolar thrombosis and the formation or organization of platelet-rich clots.
“NETs have been shown to promote tissue factor activation and fibrin deposition, consistent with our observations, suggesting a role for NETs in intra-alveolar thrombosis and the formation or organization of platelet-rich clots (43, 45).”
Quote in the paperSubstantial claim - Interpretationown data
The data support a close link between cellular senescence processes, oxidative stress, pulmonary epithelial and endothelial damage, and defective repair in lung tissue from patients with fatal COVID-19.
“Together, these data support a close link between cellular senescence processes, oxidative stress, pulmonary epithelial and endothelial damage, and defective repair in lung tissue from patients with fatal COVID-19.”
Quote in the paperSubstantial claim - Interpretationcitation
Loss of alveolar basement membrane integrity indicates excessive and persistent damage to the alveolar architecture.
“The observed loss of alveolar basement membrane integrity indicates excessive and persistent damage to the alveolar architecture, which often precedes dysregulated tissue repair processes and fibrosis (16, 17).”
Quote in the paperSubstantial claim - Interpretationown data
The finding of epithelial and endothelial cell senescence is consistent with increased susceptibility and severity of COVID-19 in the elderly and comorbid risk populations.
“Our study also demonstrated epithelial and endothelial cell senescence in the pathophysiology of COVID-19, consistent with increased susceptibility and severity of COVID-19 in the elderly and comorbid risk populations.”
Quote in the paperSubstantial claim - Interpretationcitation
Findings from this study and others indicate that inflammatory responses serve as a primary driver of the progressive and persistent pathophysiologic features of severe COVID-19.
“Findings from this study and others indicate that inflammatory responses serve as a primary driver of the progressive and persistent pathophysiologic features of severe COVID-19 (43–46).”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [43] Borges L, Pithon-Curi TC, Curi R, Hatanaka E, COVID-19 and neutrophils: The relationship between hyperinflammation and neutrophil extracellular traps. Mediat. Inflamm 2020, 1– 7 (2020). PMC7732408 33343232 source
Not checked in the free run.
- cites [44] Gustine JN, Jones D, Immunopathology of hyperinflammation in COVID-19. Am. J. Pathol 191, 4– 17 (2021). 32919977 PMC7484812 source
Not checked in the free run.
- cites [45] Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K, Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest 130, 6151– 6157 (2020). 32759504 PMC7598040 source
Not checked in the free run.
- cites [46] Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair CN, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS, Neutrophil extracellular traps in COVID-19. JCI Insight 5, e138999 (2020). 32329756 PMC7308057
Not checked in the free run.
- Rests on an assumption: Activated neutrophils, along with damaged epithelial and endothelial cells, release cytokines, chemokines, proteases, MMPs, and cytotoxic ROS, leading to DNA damage and perpetuation of alveolar destruction and respiratory dysfunction.
- Interpretationreasoning
An enhanced prothrombotic environment may result, at least in part, from prominent intravascular expression of VWF caused by endothelial injury and neutrophil-mediated proinflammatory factors as well as by reduced plasma concentrations of the natural VWF inhibitor ADAMTS13.
“An enhanced prothrombotic environment may result, at least in part, from the prominent intravascular expression of VWF caused by endothelial injury and neutrophil-mediated proinflammatory factors as well as by reduced plasma concentrations of the natural VWF inhibitor ADAMTS13.”
Quote in the paperSubstantial claim - Premisecitation
Both SARS-CoV-1 and MERS-CoV infections have been associated with long-term fibrotic lung disease.
“Both SARS-CoV-1 and MERS-CoV infections have been associated with long-term fibrotic lung disease (84, 85).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [84] Das KM, Lee EY, Singh R, Enani MA, al Dossari K, van Gorkom K, Larsson SG, Langer RD, Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J. Radiol. Imaging 27, 342– 349 (2017). 29089687 PMC5644332 source
Not checked in the free run.
- cites [85] Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, Chen L, Jiang M, Pan F, Zheng Y, Gao Z, Jiang B, Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study. Bone Res. 8, 8 (2020). 32128276 PMC7018717 source
Not checked in the free run.
- Premisecitation
Patients with severe COVID-19 were found to have a high rate of fibrotic lung function abnormalities at hospital release.
“Furthermore, patients with severe COVID-19 were found to have a high rate of fibrotic lung function abnormalities at hospital release, highlighting important implications for long-term health complications (54).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [54] Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, Lei C, Chen R, Zhong N, Li S, Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J 55, 2001217 (2020). 32381497 PMC7236826 source
Not checked in the free run.
- Interpretationown data
The findings link the induction of epithelial and endothelial senescence to oxidative stress-induced DNA damage and modulation of ROS pathways.
“Our findings here also link the induction of epithelial and endothelial senescence to oxidative stress–induced DNA damage and modulation of ROS pathways.”
Quote in the paperSubstantial claim - Premisecitation
A review of 107 patients with COVID-19 showed that 7 to 13 days after illness onset is a critical stage in this disease.
“A review of 107 patients with COVID-19 showed that 7 to 13 days after illness onset is a critical stage in this disease (67).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [67] Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, Jian M, Xu H, Prowle J, Hu B, Li Y, Peng Z, Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care 24, 188 (2020). 32354360 PMC7192564 source
Not checked in the free run.
- Interpretationcitation
The marked incorporation of PAI-1 in abnormal or persistent clots supports a plausible mechanism that may explain poor clot resolution in COVID-19.
“Microvascular endothelium is a main site of PAI-1 production, and the marked incorporation of PAI-1 in abnormal or persistent clots supports a plausible mechanism that may explain poor clot resolution in COVID-19 (57).”
Quote in the paperSubstantial claim - Interpretationcitation
The time interval between symptom onset and requirement for critical care may represent a unique therapeutic window in which to counter progressive COVID-19 pathologies.
“The time interval between symptom onset and the requirement for critical care may therefore represent a unique therapeutic window in which to counter progressive COVID-19 pathologies.”
Quote in the paperSubstantial claim - Study design and conductnone given
The overall number of patients in this case series was small.
“Whereas the present case series allowed for the examination of lung tissue from patients with COVID-19 with short, intermediate, or long clinical illness duration, the overall number of patients was small.”
Quote in the paperNot a substantial claim - Premisecitation
Correlation analysis of the severity and clinical prognosis of patients with COVID-19 demonstrated that an increase in fibrosis indicators detected at hospital admission, including hyaluronic acid, laminin, and type III procollagen, was predictive of critical illness and poor prognosis.
“Correlation analysis of the severity and clinical prognosis of patients with COVID-19 demonstrated that an increase in fibrosis indicators detected at hospital admission, including hyaluronic acid, laminin, and type III procollagen, was predictive of critical illness and poor prognosis (49).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [49] Ding M, Zhang Q, Li Q, Wu T, Huang YZ, Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19. Respir. Med 167, 105981 (2020). 32421546 PMC7167578 source
Not checked in the free run.
- Interpretationcitation
Endothelial senescence may underlie the enhanced prothrombotic properties of injured endothelium in COVID-19 by shifting the balance between anti- and procoagulant pathways.
“Endothelial senescence may underlie the enhanced prothrombotic properties of injured endothelium in COVID-19 by shifting the balance between anti- and procoagulant pathways (63).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [63] Nehme J, Borghesan M, Mackedenski S, Bird TG, Demaria M, Cellular senescence as a potential mediator of COVID-19 severity in the elderly. Aging Cell 19, e13237 (2020). 32955770 PMC7576296 source
Not checked in the free run.
- Interpretationcitation
Increased angiotensin II concentrations mediated by the actions of SARS-CoV-2 on ACE2 receptor-Ang II signaling may up-regulate ROS and cellular senescence pathways.
“Aside from the contribution of neutrophils and other cell types to ROS generation, increased angiotensin (Ang) II concentrations mediated by the actions of SARS-CoV-2 on ACE2 receptor–Ang II signaling may up-regulate ROS and cellular senescence pathways (64).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [64] Mogi M, Effect of renin-angiotensin system on senescence. Geriatr Gerontol Int 20, 520– 525 (2020). 32346971 source
Not checked in the free run.
- Premisecitation
Clinical studies have demonstrated that tocilizumab lowers all-cause mortality in patients with COVID-19.
“Clinical trials have been conducted with the IL6-blocking agent tocilizumab in patients with COVID-19 (78), and clinical studies have demonstrated efficacy in lowering all-cause mortality (79).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [79] WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, source
Not checked in the free run.
- Interpretationown data
The data presented here highlight key scientific links between these processes and common comorbidities including age, diabetes, and obesity that may help to define important determinants of disease severity and recovery.
“The data presented here highlight key scientific links between these processes and common comorbidities including age, diabetes, and obesity that may help to define important determinants of disease severity and recovery.”
Quote in the paperSubstantial claim - Premisecitation
Senescence-mediated loss of progenitor cell capabilities among AT2 and basal cell populations has been implicated in impaired reepithelialization of damaged alveoli and airways.
“Senescence-mediated loss of progenitor cell capabilities among AT2 and basal cell populations has been implicated in the impaired reepithelialization of damaged alveoli and airways (62).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [62] Kathiriya JJ, Brumwell AN, Jackson JR, Tang X, Chapman HA, Distinct airway epithelial stem cells hide among club cells but mobilize to promote alveolar regeneration. Cell Stem Cell 26, 346– 358.4 (2020). 31978363 PMC7233183 source
Not checked in the free run.
- Premisecitation
Microvascular endothelium is a main site of PAI-1 production.
“Microvascular endothelium is a main site of PAI-1 production, and the marked incorporation of PAI-1 in abnormal or persistent clots supports a plausible mechanism that may explain poor clot resolution in COVID-19 (57).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [57] Bochenek ML, Schütz E, Schäfer K, Endothelial cell senescence and thrombosis: Ageing clots. Thromb. Res 147, 36– 45 (2016). 27669126 source
Not checked in the free run.
- Interpretationown data
Aberrant clotting reactions in COVID-19 are driven by an imbalance in prothrombotic and antifibrinolytic processes.
“Collectively, these observations suggest that aberrant clotting reactions in COVID-19 are driven by an imbalance in prothrombotic and antifibrinolytic processes.”
Quote in the paperSubstantial claim - Interpretationcitation
Fibrosis may occur independently of mechanical ventilation.
“This finding suggests that fibrosis may occur independently of mechanical ventilation.”
Quote in the paperSubstantial claim
- May combine two claims. 29
- Classified as probably not a substantial claim. 13
May combine two claims.
Findingown dataCitH3-positive neutrophils were predominantly located in alveolar spaces and were more widespread in lungs from cases with short-duration disease.
“These CitH3-positive neutrophils were predominantly located in alveolar spaces and were more widespread in lungs from cases with short-duration disease (fig. S15B).”
Quote in the paperNot a substantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
May combine two claims.
Findingown dataITGA6 expression was decreased at both the mRNA level in lung and the protein level in plasma in patients with COVID-19.
“Expression of ITGA6, a cell surface marker of lung basal cells (28, 32), was decreased at both the mRNA level in lung (Fig. 1D) and at the protein level in plasma (Fig. 1E).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataMicroarray analyses identified reduced transcripts encoding endothelial junction proteins and adhesion molecules including ENG, PECAM1, VCAM1, and MCAM, and increased transcription of angiopoietin-2.
“Microarray analyses also identified reduced transcripts encoding endothelial junction proteins and adhesion molecules, including ENG, PECAM1, VCAM1, and MCAM as well as increased transcription of the gene encoding angiopoietin-2, a negative modulator of endothelial barrier dysfunction (fig. S12).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCases with intermediate illness duration showed less widespread intra-alveolar fibrin and tissue factor expression but were associated with widespread AT2 cell hyperplasia.
“Cases with intermediate illness duration showed less widespread intra-alveolar fibrin and tissue factor expression but were associated with widespread AT2 cell hyperplasia, a hallmark of organizing DAD (figs. S3F and S11, A and C).”
Quote in the paperNot a substantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
May combine two claims.
Findingown dataIn longer-duration cases, fewer MPO-positive neutrophils were generally detectable, and these cells were primarily found in alveolar fibrin balls but not in interstitial fibrotic areas.
“In longer-duration cases, fewer MPO-positive neutrophils were generally detectable, and these cells were primarily found in alveolar fibrin “balls” but not in the interstitial fibrotic areas.”
Quote in the paperNot a substantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
May combine two claims.
Findingown dataExpression of genes encoding surfactants A, B, C, and D was decreased in lung tissue from patients with COVID-19 and correlated significantly with viral load, with greater loss in patients with higher viral loads.
“The expression of genes encoding surfactants A, B, C, and D was decreased in lung tissue from patients with COVID-19 and correlated significantly (≥0.6) with viral load, with greater loss of expression observed in patients with higher viral loads (Fig. 2B).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThere was increased expression of genes encoding numerous collagens, including Col11A1 and Col14A1, which showed a positive correlation with symptom onset-to-death time.
“Consistent with gene ontology analysis, there was increased expression of genes encoding numerous collagens, including some (e.g., Col11A1 and Col14A1) that showed a positive correlation with SOTD (Fig. 4B).”
Quote in the paperSubstantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
May combine two claims.
Findingown dataVessels containing clots typically showed reduced and discontinuous staining for endothelial junction markers and were more frequently observed in short and intermediate SOTD cases than in long-duration cases.
“Vessels containing clots typically showed reduced and discontinuous staining for endothelial junction markers and were more frequently observed in short and intermediate SOTD cases than in long-duration cases.”
Quote in the paperSubstantial claim- Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
May combine two claims.
Findingnone givenIn short SOTD cases, alveolar-capillary breakdown coincided with prominent recruitment of MPO-positive neutrophils in damaged alveoli with excessive fibrin and tissue factor deposition, in thickened alveolar interstitial spaces, and along the endothelial lining of injured blood vessels.
“In short SOTD cases, alveolar-capillary breakdown coincided with prominent recruitment of MPO-positive neutrophils in damaged alveoli with excessive fibrin and tissue factor deposition, in thickened alveolar interstitial spaces, and along the endothelial lining of injured blood vessels.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataPulmonary SARS-CoV-2 infection damaged all three major components of the alveolar-capillary barrier, as evidenced by loss of alveolar epithelial and endothelial junction integrity, marked desquamation of lung AT1 and AT2 cells, and disruption of the Col IV-expressing alveolar basement membrane.
“This lung autopsy series showed that pulmonary SARS-CoV-2 infection damaged all three major components of the alveolar-capillary barrier as evidenced by the loss of alveolar epithelial and endothelial junction integrity, marked desquamation of lung AT1 and AT2 cells, and disruption of the Col IV–expressing alveolar basement membrane.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataProminent pulmonary fibrosis was observed in this lung autopsy series and correlated with SOTD and patient age.
“Prominent pulmonary fibrosis was observed in this lung autopsy series, consistent with previous reports (49–51), and correlated with SOTD and patient age (fig. S17).”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [49] Ding M, Zhang Q, Li Q, Wu T, Huang YZ, Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19. Respir. Med 167, 105981 (2020). 32421546 PMC7167578 source
Not checked in the free run.
- cites [50] George PM, Wells AU, Jenkins RG, Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med 8, 807– 815 (2020). 32422178 PMC7228727 source
Not checked in the free run.
- cites [51] Grillo F, Barisione E, Ball L, Mastracci L, Fiocca R, Lung fibrosis: An undervalued finding in COVID-19 pathological series. Lancet Infect. Dis 21, e72 (2021). 32735785 PMC7386839 source
Not checked in the free run.
May combine two claims.
Findingown dataClot-embedded PAI-1 cells stained positively for neutrophil markers MPO, neutrophil elastase, and CD15 but were negative for markers of T cells, B cells, monocytes/macrophages, and megakaryocytes/platelets.
“These clot-embedded PAI-1 cells stained positively for neutrophil markers (MPO, neutrophil elastase, and CD15) (Fig. 6C) but were negative for markers of T cells (CD3), B cells (CD20), monocytes/macrophages (CD14/CD163), or megakaryocytes/platelets (CD61/CD42b) (fig. S21).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataMany genes associated with fibrinolysis were decreased in COVID-19 lung tissue relative to normal tissue, whereas some (F12 and ANXA2) showed increased expression.
“Whereas some genes associated with fibrinolysis (F12 and ANXA2) showed increased expression, many were decreased in COVID-19 lung tissue relative to normal tissue (Fig. 5D).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe present study revealed evidence of viral antigen staining in pulmonary vascular endothelial cells in cases with short SOTD and high viral loads and a high frequency of thrombi in small- and medium-sized pulmonary blood vessels, particularly in short and intermediate SOTD cases.
“The present study revealed evidence of viral antigen staining in pulmonary vascular endothelial cells in cases with short SOTD and high viral loads and a high frequency of thrombi in small- and medium-sized pulmonary blood vessels, particularly in short and intermediate SOTD cases.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe data show that SARS-CoV-2 infection disrupts critical alveolar epithelial and endothelial function, leading to breakdown of the alveolar-capillary barrier.
“Together, these data show that SARS-CoV-2 infection disrupts critical alveolar epithelial and endothelial function leading to breakdown of the alveolar-capillary barrier.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationViral infection is mediated mainly by the binding of SARS-CoV-2 to the ACE2 receptor expressed on the surface of lung epithelial cells, endothelium, pericytes, and other cell types.
“Viral infection is mediated mainly by the binding of SARS-CoV-2 to the angiotensin–converting enzyme 2 (ACE2) receptor expressed on the surface of lung epithelial cells, endothelium, pericytes, and other cell types (1–4).”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [1] Batah SS, Fabro AT, Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir. Med 176, 106239 (2021). 33246294 PMC7674971 source
Not checked in the free run.
- cites [2] Bösmüller H, Matter M, Fend F, Tzankov A, The pulmonary pathology of COVID-19. Virchows Arch. 478, 137– 150 (2021). 33604758 PMC7892326 source
Not checked in the free run.
- cites [3] Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J, A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol 33, 2128– 2138 (2020). 32572155 PMC7306927 source
Not checked in the free run.
- cites [4] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782– 793 (2020). 32648899 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationKey risk factors associated with severe COVID-19 include advanced age (>80 years), diabetes, obesity, male gender, and hypertension.
“Key risk factors associated with severe COVID-19 include advanced age (>80 years), diabetes, obesity, male gender, and hypertension (8–12).”
Quote in the paperNot a substantial claim0 of 5 sources checked- cites [8] Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, Elsoukkary S, He B, del Vecchio C, Fortarezza F, Pezzuto F, Navalesi P, Crisanti A, Fowkes ME, Bryce CH, Calabrese F, Beasley MB, COVID-19 pulmonary pathology: A multi-institutional autopsy cohort from Italy and New York City. Mod. Pathol 33, 2156– 2168 (2020). 32879413 PMC7463226 source
Not checked in the free run.
- cites [9] de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, Bertoluci MC; Brazilian Diabetes Society Study Group (SBD), Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. Diabetol. Metab. Syndr 12, 75 (2020). 32874207 PMC7456786 source
Not checked in the free run.
- cites [10] Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, Muslin C, Jaramillo AMG, Barba-Ostria C, Cevallos-Robalino D, Sanches-SanMiguel H, Unigarro L, Zalakeviciute R, Gadian N, López-Cortés A, Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn. Microbiol. Infect. Dis 98, 115094 (2020). 32623267 PMC7260568 source
Not checked in the free run.
- cites [11] Park SC, Won SY, Kim NH, Choi H, Youk TM, Lee HJ, Jeon HH, Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections: A nationwide population-based study. Ann. Transl. Med 9, 211 (2021). 33708838 PMC7940880 source
Not checked in the free run.
- cites [12] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJM, Baillie JK, Semple MG, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 369, m1985 (2020). 32444460 PMC7243036 source
Not checked in the free run.
May combine two claims.
Interpretationown dataThe data suggest that even though lung repair processes are activated, key elements are impaired through damage and loss of critical lung basal cell populations, revealing a mechanism for impaired lung tissue repair in these patients with COVID-19.
“Collectively, these data suggest that even though lung repair processes are being activated, key elements appear to be impaired through damage and loss of critical lung basal cell populations, revealing a mechanism for impaired lung tissue repair in these patients with COVID-19.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationDirect viral infection of basal cells in fatal COVID-19 contrasts with fatal influenza viral infection, where viral replication does not occur in basal cells but associated secondary bacterial infections result in basal cell loss and lack of tissue repair and regeneration.
“Direct viral infection of basal cells in fatal COVID-19 contrasts with fatal influenza viral infection, where viral replication does not occur in basal cells but associated secondary bacterial infections result in basal cell loss and lack of tissue repair and regeneration (42).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [42] Kash JC, Walters K-A, Davis AS, Sandouk A, Schwartzman LM, Jagger BW, Chertow DS, Li Q, Kuestner RE, Ozinsky A, Taubenberger JK, Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio 2, e00172– 11 (2011). 21933918 PMC3175626 source
Not checked in the free run.
May combine two claims.
PremisecitationDAD and alveolar-capillary barrier breakdown are prominent pathological features of severe COVID-19.
“DAD and alveolar-capillary barrier breakdown are prominent pathological features of severe COVID-19 (1–4).”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [1] Batah SS, Fabro AT, Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir. Med 176, 106239 (2021). 33246294 PMC7674971 source
Not checked in the free run.
- cites [2] Bösmüller H, Matter M, Fend F, Tzankov A, The pulmonary pathology of COVID-19. Virchows Arch. 478, 137– 150 (2021). 33604758 PMC7892326 source
Not checked in the free run.
- cites [3] Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J, A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol 33, 2128– 2138 (2020). 32572155 PMC7306927 source
Not checked in the free run.
- cites [4] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782– 793 (2020). 32648899 source
Not checked in the free run.
May combine two claims.
PremisecitationNETs promote tissue factor activation and fibrin deposition.
“NETs have been shown to promote tissue factor activation and fibrin deposition, consistent with our observations, suggesting a role for NETs in intra-alveolar thrombosis and the formation or organization of platelet-rich clots (43, 45).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [43] Borges L, Pithon-Curi TC, Curi R, Hatanaka E, COVID-19 and neutrophils: The relationship between hyperinflammation and neutrophil extracellular traps. Mediat. Inflamm 2020, 1– 7 (2020). PMC7732408 33343232 source
Not checked in the free run.
- cites [45] Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K, Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest 130, 6151– 6157 (2020). 32759504 PMC7598040 source
Not checked in the free run.
May combine two claims.
Interpretationown dataPulmonary SARS-CoV-2 infection disrupts the balance between normal tissue regeneration and pathological fibrosis, promotes increased and unresolving vascular thrombosis, and elicits production of damaging proinflammatory mediators and ROS.
“Collectively, these findings indicate that pulmonary SARS-CoV-2 infection disrupts the balance between normal tissue regeneration and pathological fibrosis, promotes increased and unresolving vascular thrombosis, and elicits production of damaging proinflammatory mediators and ROS.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataIn cases with a longer disease duration, disease progression led to excessive pulmonary fibrosis, loss of alveoli, and vascular remodeling.
“Furthermore, in cases with a longer disease duration, disease progression led to excessive pulmonary fibrosis, loss of alveoli, and vascular remodeling.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataPAI-1-labeled neutrophils have a nonapoptotic and non-NET-producing phenotype.
“These PAI-1–labeled neutrophils were also negative for cleaved caspase 3 and CitH3, suggesting a nonapoptotic and non–NET-producing phenotype, respectively (figs. S21 and S15D).”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataBoth direct virus-induced cytopathic effects and host inflammatory and immune responses led to early pulmonary epithelial and endothelial injury, alveolar-capillary barrier dysfunction, impaired lung tissue repair processes, and widespread vascular thrombosis with reduced fibrinolysis.
“Pathological observations indicated that both direct virus-induced cytopathic effects and host inflammatory and immune responses led to early pulmonary epithelial and endothelial injury, alveolar-capillary barrier dysfunction, impaired lung tissue repair processes, and widespread vascular thrombosis with reduced fibrinolysis.”
Quote in the paperSubstantial claim- Rests on an assumption: Activated neutrophils, along with damaged epithelial and endothelial cells, release cytokines, chemokines, proteases, MMPs, and cytotoxic ROS, leading to DNA damage and perpetuation of alveolar destruction and respiratory dysfunction.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationSenescent cells exhibit a senescence-associated secretory phenotype (SASP) characterized by overproduction of proinflammatory molecules such as IL6, TGFβ, IL8, MCP-1, extracellular matrix remodeling enzymes (MMPs), serine/cysteine proteinase inhibitors (serpins), and tissue inhibitors of metalloproteinases.
“Senescent cells exhibit a senescence-associated secretory phenotype (SASP) characterized by an overproduction of proinflammatory molecules such as IL6, TGFβ, IL8, MCP-1, extracellular matrix remodeling enzymes (MMPs), serine/cysteine proteinase inhibitors (serpins), and tissue inhibitors of metalloproteinases (61).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [61] He S, Sharpless NE, Senescence in health and disease. Cell 169, 1000– 1011 (2017). 28575665 PMC5643029 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataBecause all cases in this study were fatal, it is unknown to what extent these pathological processes occur in mild to moderate or hospitalized, nonfatal COVID-19 cases or in cases with long-term sequelae after SARS-CoV-2 infection.
“Last, because all cases in this study were fatal, it is unknown to what extent these pathological processes occur in mild to moderate or hospitalized, nonfatal COVID-19 cases or in cases with long-term sequelae after SARS-CoV-2 infection.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationA systematic review of 45 studies of chest computed tomography images of patients with COVID-19 demonstrated pulmonary fibrosis in 17% of patients, which was attributed to impaired healing after viral infection of lung AT2 cells.
“A systematic review of 45 studies of chest computed tomography images of patients with COVID-19 demonstrated pulmonary fibrosis in 17% of patients, which was attributed to impaired healing after viral infection of lung AT2 cells (53).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [53] Ojha V, Mani A, Pandey NN, Sharma S, Kumar S, CT in coronavirus disease 2019 (COVID-19): A systematic review of chest CT findings in 4410 adult patients. Eur. Radiol 30, 6129– 6138 (2020). 32474632 PMC7261039 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenIngenuity pathway analysis was used for gene ontology enrichment using Bonferroni correction.
“Ingenuity pathway analysis was used for gene ontology enrichment using Bonferroni correction.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationClinical trials have shown reduced mortality in patients with influenza A/H7N9 virus-induced ARDS treated with transplanted MSCs.
“Clinical trials have shown reduced mortality in patients with influenza A/H7N9 virus–induced ARDS treated with transplanted MSCs, and ongoing trials are currently investigating stem cell therapies for treating patients with COVID-19 (83).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [83] Yadav P, Vats R, Bano A, Bhardwaj R, Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci. 263, 118588 (2020). 33049279 PMC7547615 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationA recent study reported a correlation between elevated PAI-1 plasma concentrations and circulating neutrophils in patients with COVID-19.
“A recent study reported a correlation between elevated PAI-1 plasma concentrations and circulating neutrophils in patients with COVID-19 (58).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [58] Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, Madison JA, Knight JS, Kanthi Y, Lawrence DA, Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. medRxiv, 1580 (2020). PMC7810990 33452298
Not checked in the free run.
Probably not a substantial claim: may not pass S1 (asserted), S3 (load-bearing).
PremisecitationTargeting surfactant deficiency may improve respiratory function in patients with COVID-19.
“Others have reported that targeting surfactant deficiency may improve respiratory function in patients with COVID-19 (80, 81).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [80] Mirastschijski U, Dembinski R, Maedler K, Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia. Front. Med 7, 254 (2020). PMC7256165 32574339 source
Not checked in the free run.
- cites [81] Piva S, DiBlasi RM, Slee AE, Jobe AH, Roccaro AM, Filippini M, Latronico N, Bertoni M, Marshall JC, Portman MA, Surfactant therapy for COVID-19 related ARDS: A retrospective case-control pilot study. Respir. Res 22, 20 (2021). 33461535 PMC7812332 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationTreatment with corticosteroids has shown some efficacy against COVID-19.
“Treatment with corticosteroids, that act on multiple anti-inflammatory pathways (75), has shown some efficacy against COVID-19 (76).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [76] Jensen MP, George M, Gilroy D, Sofat R, Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. Br. J. Clin. Pharmacol 87, 845– 857 (2021). 32881064 source
Not checked in the free run.
May combine two claims.
PremisecitationAmong patients who developed severe disease, median time to dyspnea was 5 to 8 days, median time to ARDS was 8 to 12 days, and median time to intensive care unit admission was 10 to 12 days after symptom onset.
“Additional studies found that, among patients who developed severe disease, the median time to dyspnea was 5 to 8 days, the median time to ARDS was 8 to 12 days, and the median time to intensive care unit admission was 10 to 12 days after symptom onset (68–70).”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [68] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497– 506 (2020). 31986264 PMC7159299 source
Not checked in the free run.
- cites [69] Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, Lu H, Liu J, Yang J, Dong Y, Pan D, Shu C, Li J, Wei J, Huang Y, Peng L, Wu M, Zhang R, Wu B, Li Y, Cai L, Li G, Zhang T, Wu G, Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol. 21, 904– 913 (2020). 32479787 PMC7259917 source
Not checked in the free run.
- cites [70] Zhou F, Yu T, du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395, 1054– 1062 (2020). 32171076 PMC7270627 source
Not checked in the free run.
May combine two claims.
PremisecitationVascular dysfunction and thrombotic complications are hallmark features of COVID-19.
“Vascular dysfunction and thrombotic complications are hallmark features of COVID-19 (55).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [55] Ahmed S, Zimba O, Gasparyan AY, Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin. Rheumatol 39, 2529– 2543 (2020). 32654082 PMC7353835 source
Not checked in the free run.
May combine two claims.
PremisecitationKey clinical risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all characterized by activation or exacerbation of cellular senescence processes.
“Key clinical risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all characterized by the activation or exacerbation of cellular senescence processes (66).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [66] Jia G, Aroor AR, Jia C, Sowers JR, Endothelial cell senescence in aging-related vascular dysfunction. Biochim. Biophys. Acta Mol. basis Dis 1865, 1802– 1809 (2019). 31109450 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenIt is a potential concern whether the available lung specimens used for imaging and transcriptomic analyses were representative of the whole lung.
“Another potential concern is related to lung tissue sampling and, specifically, whether the available lung specimens used for imaging and transcriptomic analyses were representative of the whole lung.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductown dataControl lung sections were histologically defined as normal by a certified pathologist using routine H&E staining.
“These lung sections were histologically defined as normal by a certified pathologist using routine H&E staining.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationROS scavengers have shown efficacy in influenza.
“ROS scavengers have shown efficacy in influenza (77), which, as noted, has certain clinical and pathologic similarities to COVID-19.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [77] Kash JC, Xiao Y, Davis AS, Walters KA, Chertow DS, Easterbrook JD, Dunfee RL, Sandouk A, Jagger BW, Schwartzman LM, Kuestner RE, Wehr NB, Huffman K, Rosenthal RA, Ozinsky A, Levine RL, Doctrow SR, Taubenberger JK, Treatment with the reactive oxygen species scavenger EUK-207 reduces lung damage and increases survival during 1918 influenza virus infection in mice. Free Radic. Biol. Med 67, 235– 247 (2014). 24140866 PMC3927540 source
Not checked in the free run.
May combine two claims.
PremisecitationRisk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all associated with increased plasma PAI-1 concentrations.
“It may be particularly relevant that risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all associated with increased plasma PAI-1 concentrations (59, 60).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [59] Alessi MC, Juhan-Vague I, PAI-1 and the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol 26, 2200– 2207 (2006). 16931789 source
Not checked in the free run.
- cites [60] Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H, Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: Implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc. Res 66, 276– 285 (2005). 15820196 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenStatistical analysis included standard t test using Benjamini-Hochberg procedure to correct for the false-positive rate in multiple comparisons.
“Statistical analysis included standard t test using Benjamini-Hochberg procedure to correct for the false-positive rate in multiple comparisons.”
- Also stated in: § Microarray gene expression profiling · plain
“The Benjamini-Hochberg procedure was used to correct for the false-positive rate in multiple comparisons.”
Quote in the paperNot a substantial claim- Also stated in: § Microarray gene expression profiling · plain
The paper relies on this without support.
The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
“Postmortem lung autopsy samples (n = 18) and antemortem plasma samples (from six of the cases) were collected from a case series of confirmed SARS-CoV-2–positive patients who died between March and July 2020.”
The paper relies on this without support.
The 18 fatal COVID-19 autopsy cases are representative of fatal COVID-19 generally.
“Postmortem lung autopsy samples (n = 18) and antemortem plasma samples (from six of the cases) were collected from a case series of confirmed SARS-CoV-2–positive patients who died between March and July 2020.”
The paper relies on this without support.
The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
“To further characterize histological indices of DAD progression in relation to clinical illness duration, serial lung sections were stained with H&E or for fibrin, tissue factor, collagen type 1 (Col 1), and α–smooth muscle actin (αSMA).”
The paper relies on this without support.
Pathologic changes likely occurred asynchronously throughout the lung.
“Although pathologic changes likely occurred asynchronously throughout the lung and each case examined resulted in a fatal outcome regardless of SOTD duration, these observations nevertheless suggested a temporal framework for disease progression that outlines a natural history and pathogenesis of SARS-CoV-2 infection (fig. S17).”
The paper relies on this without support.
Activated neutrophils, along with damaged epithelial and endothelial cells, release cytokines, chemokines, proteases, MMPs, and cytotoxic ROS, leading to DNA damage and perpetuation of alveolar destruction and respiratory dysfunction.
“Activated neutrophils, along with damaged epithelial and endothelial cells, release a host of cytokines, chemokines, proteases, MMPs, and cytotoxic ROS, leading to DNA damage and perpetuation of alveolar destruction and respiratory dysfunction.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A panel of senescence markers distinguishes nasopharyngeal mucosa from COVID-19 patients versus pre-pandemic controls, with higher reactivity in COVID-19 samples.
“when comparing samples of nasopharyngeal mucosa from patients with COVID-19 to pre-pandemic biopsy samples from individuals without a manifest respiratory tract infection, a panel of senescence markers was shown to robustly discriminate these two groups, with significantly higher reactivity in samples from patients with COVID-19 (refs.28,29,44,52).”
From COVID-19 and cellular senescence (2023) · cites this paper as [52]
Lung specimens from COVID-19 patients show much stronger signs of senescence than SARS-CoV-2 negative controls.
“Similar analyses of lung specimens from patients with COVID-19, consistent with multiple independent patient datasets29,44,52, also showed much stronger signs of senescence compared to SARS-CoV-2 negative controls28.”
From COVID-19 and cellular senescence (2023) · cites this paper as [52]
SASP-typical cytokines, extracellular matrix-active proteases, and SASP-related pro-coagulant and complement-activating factors are strongly elevated in the serum of COVID-19 patients compared with healthy controls.
“were also strongly elevated in the serum of patients with COVID-19 compared to healthy controls28,52,67–70.”
From COVID-19 and cellular senescence (2023) · cites this paper as [52]
SARS-CoV-2 triggers a profibrotic response in CD14+CD163+ macrophages that promotes pulmonary fibrosis and acute respiratory distress syndrome.
“SARS-CoV-2 triggers a profibrotic response in CD14+CD163+ macrophages, which promotes manifest pulmonary fibrosis and acute respiratory distress syndrome (Box 1)”
From COVID-19 and cellular senescence (2023) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Plasma protein elevations attributed to lung tissue
MinorThe results say these plasma proteins were elevated in lung tissue, but the methods describe measuring proteins in plasma and analyzing lung tissue for gene expression. The specimen in which the protein elevations were measured is therefore inconsistent.
“Plasma proteins associated with neutrophil and ROS responses including IL8, CXCL10, and EN-RAGE primarily derived from activated neutrophils (37), IL6, and PRDX1 were also elevated in lung tissue from patients with COVID-19 (Fig. 3E).”
“To characterize host responses, postmortem lung tissues were analyzed by expression microarray analysis, and antemortem plasma samples were analyzed by multiplexed protein assays.”
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · see citing works
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works
Self-citationBerman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196 · see citing works
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · see citing works
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022 · see citing works
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling
Guex, N., & Peitsch, M. (1997) · Electrophoresis · doi:10.1002/elps.1150181505 · Cited by 11,589 · see citing works
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,477 · see citing works
Improved metagenomic analysis with Kraken 2
Wood, D. E., Lu, J., & Langmead, B. (2019) · Genome biology · doi:10.1186/s13059-019-1891-0 · Cited by 7,173 · see citing works
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,822 · see citing works
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609 · see citing works
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
Shi, H., Han, X., Jiang, N., Cao, Y., Alwalid, O., Gu, J., Fan, Y., & Zheng, C. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30086-4 · Cited by 3,664 · see citing works
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481 · see citing works
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229 · see citing works
Senescence in Health and Disease
He, S., & Sharpless, N. E. (2017) · Cell · doi:10.1016/j.cell.2017.05.015 · Cited by 1,766 · see citing works
Neutrophil extracellular traps in COVID-19
Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J. A., Blair, C., Weber, A. G., Barnes, B. J., Egeblad, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138999 · Cited by 1,602 · see citing works
Basal cells as stem cells of the mouse trachea and human airway epithelium
Rock, J. R., Onaitis, M. W., Rawlins, E. L., Lu, Y., Clark, C. P., Xue, Y., Randell, S. H., & Hogan, B. L. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906850106 · Cited by 1,568 · see citing works
VarScan: variant detection in massively parallel sequencing of individual and pooled samples
Koboldt, D. C., Chen, K., Wylie, T., Larson, D. E., McLellan, M. D., Mardis, E. R., Weinstock, G. M., Wilson, R. K., & Ding, L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp373 · Cited by 1,351 · see citing works
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
Al-Samkari, H. T., Leaf, R. K., Dzik, S., Carlson, J., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., et al. (2020) · Blood · doi:10.1182/blood.2020006520 · Cited by 1,342 · see citing works
Genetic mechanisms of critical illness in COVID-19
The GenOMICC Investigators, Pairo‐Castineira, E., The ISARIC4C Investigators, Initiative, T. C.-1. H. G., 23andMe Investigators, BRACOVID Investigators, Gen-COVID Investigators, Clohisey, S., Klarić, L., Bretherick, A. D., et al. (2020) · Nature · doi:10.1038/s41586-020-03065-y · Cited by 1,335 · see citing works
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261 · cited 1× · see citing works
“Potential therapeutic approaches targeting cellular senescence to improve epithelial and endothelial cell function include the use of senolytic compounds, such as ABT-263 (Navitoclax), which promote clearance of senescent cells by inhibiting prosurvival pathways (91–93).”
BackgroundPulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085 · see citing works
Hogan, B. L. M., Barkauskas, C. E., Chapman, H. A., Epstein, J. A., Jain, R., Hsia, C. C. W., Niklason, L., Calle, E., Le, A., Randell, S. H., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.07.012 · Cited by 876 · see citing works
How corticosteroids control inflammation: Quintiles Prize Lecture 2005
Barnes, P. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706736 · Cited by 842 · see citing works
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge
Mo, X., Jian, W., Su, Z., Chen, M., Peng, H., Peng, P., Lei, C., Chen, R., Zhong, N., & Li, S. (2020) · European Respiratory Journal · doi:10.1183/13993003.01217-2020 · Cited by 810 · see citing works
Skendros, P., Mitsios, A., Chrysanthopoulou, A., Mastellos, D. C., Metallidis, S., Rafailidis, P., Ntinopoulou, M., Sertaridou, E., Tsironidou, V., Tsigalou, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141374 · Cited by 786 · see citing works
Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling
Rock, J. R., Randell, S. H., & Hogan, B. L. M. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.006031 · Cited by 724 · see citing works
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Domingo, P., Mur, I., Mateo, G. M., Gutierrez, M. D. M., Pomar, V., de Benito, N., Corbacho, N., Herrera, S., Millan, L., et al. (2021) · JAMA · doi:10.1001/jama.2021.11330 · Cited by 678 · see citing works
Structural basis of a shared antibody response to SARS-CoV-2
Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., et al. (2020) · Science · doi:10.1126/science.abd2321 · Cited by 589 · see citing works
Yang, K., Sheng, Y., Huang, C., Jin, Y., Xiong, N., Jiang, K., Lu, H., Liu, J., Yang, J., Dong, Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30310-7 · Cited by 584 · see citing works
Immunopathology of Hyperinflammation in COVID-19
Gustine, J. N., & Jones, D. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.009 · Cited by 516 · see citing works
Lee, J., Bhang, D. H., Beede, A. M., Huang, T. L., Stripp, B. R., Bloch, K. D., Wagers, A. J., Tseng, Y., Ryeom, S. W., & Kim, C. F. (2014) · Cell · doi:10.1016/j.cell.2013.12.039 · Cited by 491 · see citing works
Polak, S. B., Van Gool, I. C., Cohen, D., von der Thüsen, J. H., & van Paassen, J. (2020) · Modern Pathology · doi:10.1038/s41379-020-0603-3 · Cited by 481 · see citing works
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458 · see citing works
Endothelial cell senescence in aging-related vascular dysfunction
Jia, G., Aroor, A. R., Jia, C., & Sowers, J. R. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.008 · Cited by 454 · see citing works
COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
Borczuk, A. C., Salvatore, S. P., Seshan, S. V., Patel, S. S., Bussel, J. B., Mostyka, M., Elsoukkary, S., He, B., Del Vecchio, C., Fortarezza, F., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00661-1 · Cited by 452 · see citing works
The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections
Han, S., & Mallampalli, R. K. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201411-507fr · Cited by 442 · see citing works
Zhang, P., Li, J., Liu, H., Han, N., Ju, J., Kou, Y., Chen, L., Jiang, M., Pan, F., Zheng, Y., et al. (2020) · Bone Research · doi:10.1038/s41413-020-0084-5 · Cited by 440 · see citing works
Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., Costa, R., Schiller, H. B., Lindner, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02367-2016 · Cited by 403 · see citing works
Wang, D., Yin, Y., Hu, C., Liu, X., Zhang, X., Zhou, S., Jian, M., Xu, H., Prowle, J., Hu, B., et al. (2020) · Critical Care · doi:10.1186/s13054-020-02895-6 · Cited by 397 · see citing works
de Almeida-Pititto, B., Dualib, P. M., Zajdenverg, L., Dantas, J. R., de Souza, F. D., Rodacki, M., Bertoluci, M. C., & Brazilian Diabetes Society Study Group (SBD) (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00586-4 · Cited by 391 · see citing works
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390 · see citing works
APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort
Kuo, C.-L., Pilling, L. C., Atkins, J. L., Masoli, J. A. H., Delgado, J., Kuchel, G. A., & Melzer, D. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glaa131 · Cited by 388 · see citing works
Follow-up chest radiographic findings in patients with MERS-CoV after recovery
Das, K. M., Lee, E. Y., Singh, R., Enani, M. A., Al Dossari, K., Van Gorkom, K., Larsson, S. G., & Langer, R. D. (2017) · Indian Journal of Radiology and Imaging · doi:10.4103/ijri.ijri_469_16 · Cited by 370 · see citing works
SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation
Li, S., Zhang, Y., Guan, Z., Li, H., Ye, M., Chen, X., Shen, J., Zhou, Y., Shi, Z.-L., Zhou, P., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00334-0 · Cited by 365 · see citing works
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
Lv, Z., Deng, Y., Ye, Q., Cao, L., Sun, C.-Y., Fan, C., Huang, W., Sun, S., Sun, Y., Zhu, L., et al. (2020) · Science · doi:10.1126/science.abc5881 · Cited by 362 · see citing works
Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians
Batah, S. S., & Fabro, A. T. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106239 · Cited by 319 · see citing works
SARS‐CoV‐2 viral spike G614 mutation exhibits higher case fatality rate
Becerra‐Flores, M., & Cardozo, T. J. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13525 · Cited by 291 · see citing works
Targeting senescent cells in translational medicine
Pàez‐Ribes, M., González‐Gualda, E., Doherty, G. J., & Muñoz‐Espín, D. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810234 · Cited by 289 · see citing works
COVID–19-associated coagulopathy: An exploration of mechanisms
Colling, M. E., & Kanthi, Y. M. (2020) · Vascular Medicine · doi:10.1177/1358863x20932640 · Cited by 276 · see citing works
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
Gómez, C. E., Perdiguero, B., & Estéban, M. (2021) · Vaccines · doi:10.3390/vaccines9030243 · Cited by 262 · see citing works
Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence
Vaughan, D. E., Rai, R., Khan, S. S., Eren, M., & Ghosh, A. K. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309451 · Cited by 258 · see citing works
Rabaan, A. A., Al-Ahmed, S. H., Muhammad, J., Khan, A., Sule, A. A., Tirupathi, R., Mutair, A. S. A., Alhumaid, S., Al‐Omari, A., Dhawan, M. K., et al. (2021) · Vaccines · doi:10.3390/vaccines9050436 · Cited by 255 · see citing works
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05275-1 · Cited by 251 · see citing works
Kathiriya, J. J., Brumwell, A. N., Jackson, J. R., Tang, X., & Chapman, H. A. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.12.014 · Cited by 246 · see citing works
Two distinct immunopathological profiles in autopsy lungs of COVID-19
Nienhold, R., Ciani, Y., Koelzer, V. H., Tzankov, A., Haslbauer, J. D., Menter, T., Schwab, N., Henkel, M., Frank, A., Zsikla, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18854-2 · Cited by 246 · see citing works
Borges, L., Pithon-Curi, T. C., Curi, R., & Hatanaka, E. (2020) · Mediators of Inflammation · doi:10.1155/2020/8829674 · Cited by 235 · see citing works
Zuo, Y., Warnock, M., Harbaugh, A., Yalavarthi, S., Gockman, K., Zuo, M., Madison, J. A., Knight, J. S., Kanthi, Y. M., & Lawrence, D. A. (2021) · Scientific Reports · doi:10.1038/s41598-020-80010-z · Cited by 234 · see citing works
Ojha, V., Mani, A., Pandey, N. N., Sharma, S., & Kumar, S. (2020) · European Radiology · doi:10.1007/s00330-020-06975-7 · Cited by 227 · see citing works
YAMAMOTO, K., TAKESHITA, K., KOJIMA, T., TAKAMATSU, J., & SAITO, H. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.11.013 · Cited by 214 · see citing works
Englert, J. A., Bobba, C. M., & Baron, R. M. (2019) · JCI Insight · doi:10.1172/jci.insight.124061 · Cited by 204 · see citing works
Mackman, N., Antoniak, S., Wolberg, A. S., Kasthuri, R. S., & Key, N. S. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314514 · Cited by 186 · see citing works
Zhang, Y., Qin, L., Zhao, Y., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa224 · Cited by 183 · see citing works
The pulmonary pathology of COVID-19
Bösmüller, H., Matter, M., Fend, F., & Tzankov, A. (2021) · Virchows Archiv · doi:10.1007/s00428-021-03053-1 · Cited by 180 · see citing works
Breaking Barriers. New Insights into Airway Epithelial Barrier Function in Health and Disease
Rezaee, F., & Georas, S. N. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0541rt · Cited by 172 · see citing works
Krafft, A. E., Duncan, B., Bijwaard, K. E., Taubenberger, J. K., & Lichy, J. H. (1997) · Molecular Diagnosis · doi:10.1016/s1084-8592(97)80032-x · Cited by 158 · see citing works
Self-citationBastarache, J. A., Wang, L., Geiser, T., Wang, Z., Albertine, K. H., Matthay, M. A., & Ware, L. B. (2007) · Thorax · doi:10.1136/thx.2006.063305 · Cited by 148 · see citing works
Kash, J. C., Walters, K.-A., Davis, A. S., Sandouk, A., Schwartzman, L. M., Jagger, B. W., Chertow, D. S., Qi, L., Kuestner, R. E., Ozinsky, A., et al. (2011) · mBio · doi:10.1128/mbio.00172-11 · Cited by 143 · see citing works
Self-citationKambas, K., Markiewski, M. M., Pneumatikos, I. A., Rafail, S. S., Theodorou, V., Konstantonis, D., Kourtzelis, I., Doumas, M. N., Magotti, P., DeAngelis, R. A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7368 · Cited by 127 · see citing works
Lung fibrosis: an undervalued finding in COVID-19 pathological series
Grillo, F., Barisione, E., Ball, L., Mastracci, L., & Fiocca, R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30582-x · Cited by 121 · see citing works
Kása, A., Csoŕtos, C., & Verin, A. D. (2014) · Tissue Barriers · doi:10.4161/21688370.2014.974448 · Cited by 119 · see citing works
A proposal for staging COVID‐19 coagulopathy
Thachil, J. V., Cushman, M., Srivastava, A., & Angchaisuksiri, P. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12372 · Cited by 118 · see citing works
Anticoagulation and bleeding risk in patients with COVID-19
Musoke, N., Lo, K. B., Albano, J., Peterson, E., Bhargav, R., Gul, F., DeJoy, R., Salacup, G., Pelayo, J., Tipparaju, P., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.08.035 · Cited by 117 · see citing works
Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis
Li, Z., Niu, S., Guo, B., Gao, T., Wang, L., Wang, Y., Wang, L., Tan, Y., Wu, J., & Hao, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12939 · Cited by 105 · see citing works
Sauter, J. L., Baine, M. K., Butnor, K. J., Buonocore, D. J., Chang, J. C., Jungbluth, A. A., Szabolcs, M. J., Morjaria, S., Mount, S. L., Rekhtman, N., et al. (2020) · Histopathology · doi:10.1111/his.14201 · Cited by 104 · see citing works
Self-citationAntwi‐Amoabeng, D., Kanji, Z., Ford, B., Beutler, B. D., Riddle, M. S., & Siddiqui, F. A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26038 · Cited by 101 · see citing works
Endothelial cell senescence and thrombosis: Ageing clots
Bochenek, M. L., Schütz, E., & Schäfer, K. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.09.019 · Cited by 96 · see citing works
Bansal, R., Nakagawa, S., Yazdani, S., van Baarlen, J., Venkatesh, A., Koh, A. P., Song, W.-M., Goossens, N., Watanabe, H., Beasley, M. B., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.213 · Cited by 96 · see citing works
Cellular senescence as a potential mediator of COVID‐19 severity in the elderly
Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G., & Demaria, M. (2020) · Aging Cell · doi:10.1111/acel.13237 · Cited by 94 · see citing works
Guzy, R., Stoilov, I., Elton, T. J., Mecham, R., & Ornitz, D. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0184oc · Cited by 93 · see citing works
Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia
Mirastschijski, U., Dembinski, R., & Maedler, K. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00254 · Cited by 90 · see citing works
Reynolds, S. D., Giangreco, A., Hong, K. U., McGrath, K. E., Ortiz, L. A., & Stripp, B. R. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00203.2004 · Cited by 86 · see citing works
Wang, L., Balmat, T. J., Antonia, A. L., Constantine, F. J., Henao, R., Burke, T. W., Ingham, A., McClain, M. T., Tsalik, E. L., Ko, E. R., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00904-z · Cited by 86 · see citing works
Yanagi, S., Tsubouchi, H., Miura, A., Matsumoto, N., & Nakazato, M. (2015) · BioMed Research International · doi:10.1155/2015/573210 · Cited by 71 · see citing works
Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study
Piva, S., DiBlasi, R. M., Slee, A. E., Jobe, A. H., Roccaro, A. M., Filippini, M., Latronico, N., Bertoni, M., Marshall, J. C., & Portman, M. A. (2021) · Respiratory Research · doi:10.1186/s12931-020-01603-w · Cited by 70 · see citing works
Allegra, A., Innao, V., Allegra, A. G., & Musolino, C. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04182-4 · Cited by 67 · see citing works
Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19
Ding, M., Zhang, Q., Li, Q., Wu, T., & Huang, Y.-Z. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.105981 · Cited by 60 · see citing works
FGFR2 is required for airway basal cell self-renewal and terminal differentiation
Balasooriya, G. I., Goschorska, M., Piddini, E., & Rawlins, E. L. (2017) · Development · doi:10.1242/dev.135681 · Cited by 53 · see citing works
Production of amphiregulin and recovery from influenza is greater in males than females
Vermillion, M. S., Ursin, R. L., Kuok, D. I. T., Steeg, L. G. V., Wohlgemuth, N., Hall, O. J., Fink, A. L., Sasse, E., Nelson, A., Ndeh, R., et al. (2018) · Biology of Sex Differences · doi:10.1186/s13293-018-0184-8 · Cited by 53 · see citing works
Effect of renin–angiotensin system on senescence
Mogi, M. (2020) · Geriatrics & Gerontology International · doi:10.1111/ggi.13927 · Cited by 48 · see citing works
Barrett, C. D., Moore, H. B., Moore, E. E., McIntyre, R. C., Moore, P. K., Burke, J., Hua, F., Apgar, J. F., Talmor, D. S., Sauaia, A., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12357 · Cited by 48 · see citing works
Kash, J. C., Xiao, Y., Davis, A. S., Walters, K.-A., Chertow, D. S., Easterbrook, J. D., Dunfee, R. L., Sandouk, A., Jagger, B. W., Schwartzman, L. M., et al. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.10.014 · Cited by 43 · see citing works
Self-citationRegeneration and repair in the healing lung
Lucas, A., Yasa, J., & Lucas, M. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1152 · Cited by 41 · see citing works
Vegivinti, C. T. R., Pederson, J. M., Saravu, K., et al. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.12.051 · Cited by 41 · see citing works
Network-Based Analysis of Fatal Comorbidities of COVID-19 and Potential Therapeutics
Chakrabarty, B., Das, D., Bulusu, G., & Roy, A. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3075299 · Cited by 38 · see citing works
Yadav, P., Vats, R., Bano, A., & Bhardwaj, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118588 · Cited by 36 · see citing works
Current COVID-19 treatments: Rapid review of the literature
Dong, Y., Shamsuddin, A., Campbell, H. J., & Τheodoratou, E. (2021) · Journal of Global Health · doi:10.7189/jogh.11.10003 · Cited by 36 · see citing works
Zuo, Y., Warnock, M., Harbaugh, A., et al. (2020) · medRxiv · doi:10.1101/2020.08.29.20184358 · Cited by 35 · see citing works
Nikoloudis, D., Kountouras, D., & Hiona, A. (2020) · PeerJ · doi:10.7717/peerj.10402 · Cited by 34 · see citing works
Asakura, H., & Ogawa, H. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-00491-y · Cited by 27 · see citing works
Wang, L., Balmat, T. J., Antonia, A. L., et al. (2020) · medRxiv · doi:10.1101/2020.12.20.20248572 · Cited by 25 · see citing works
Berrocal-Almanza, L. C., Goyal, S., Hussain, A., et al. (2016) · Scientific Reports · doi:10.1038/srep31798 · Cited by 20 · see citing works
Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19
Jensen, M. P., George, M., Gilroy, D., & Sofat, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14540 · Cited by 17 · see citing works
Stem cell factor improves lung recovery in rats following neonatal hyperoxia-induced lung injury
de Miranda, L. F. J. R., Rodrigues, C. O., Ramachandran, S., et al. (2013) · Pediatric Research · doi:10.1038/pr.2013.165 · Cited by 17 · see citing works
Park, S. C., Won, S. Y., Kim, N. H., Choi, H., Youk, T. M., Lee, H. J., & Jeon, H. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5958 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
COVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153 · see citing works
Emerging functions of thrombospondin-1 in immunity
Kaur, S., & Roberts, D. D. (2024) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2023.05.008 · Cited by 96 · see citing works
Wang, J., Zhou, X., Yu, P., Yao, J., Guo, P., Xu, Q., Zhao, Y., Wang, G., Li, Q., Zhu, X., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00886-2 · Cited by 28 · see citing works
- Authors
- D’Agnillo, F., Walters, K.-A., Xiao, Y., Sheng, Z.-M., Scherler, K., Park, J., Gygli, S., Rosas, L. A., Sadtler, K., Kalish, H., Blatti, C. A., Zhu, R., Gatzke, L., Bushell, C., Memoli, M. J., O’Day, S. J., Fischer, T. D., Hammond, T. C., Lee, R. C., Cash, J. C., Powers, M. E., O’Keefe, G. E., Butnor, K. J., Rapkiewicz, A. V., Travis, W. D., Layne, S. P., Kash, J. C., & Taubenberger, J. K.
- Affiliations
- Center for Biologics Evaluation and Research (US)
- Institute for Systems Biology (US)
- National Institutes of Health (US)
- Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
- University of Illinois Urbana-Champaign (US)
- Saint John’s Cancer Institute, Santa Monica, CA, USA.
- Saint John's Health Center (US)
- University of Southern California (US)
- University of Washington (US)
- University of Vermont Medical Center (US)
- NYU Grossman Long Island School of Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- D’Agnillo, Felice
- Walters, Kathie-Anne
- Xiao, Yongli
- Sheng, Zong-Mei
- Taubenberger, Jeffery K.
- ORCID
- D’Agnillo, Felice
- Walters, Kathie-Anne
- Xiao, Yongli
- Scherler, Kelsey
- Park, Jaekeun
- Gygli, Sebastian
- Rosas, Luz Angela
- Sadtler, Kaitlyn
- Kalish, Heather
- Blatti, Charles A.
- Zhu, Ruoqing
- Gatzke, Lisa
- Bushell, Colleen
- Memoli, Matthew J.
- Fischer, Trevan D.
- Hammond, Terese C.
- Powers, Matthew E.
- O’Keefe, Grant E.
- Butnor, Kelly J.
- Rapkiewicz, Amy V.
- Travis, William D.
- Layne, Scott P.
- Kash, John C.
- Taubenberger, Jeffery K.
- Venue
- Science Translational Medicine
- Published
- 2021-11-17
- Volume
- 13
- Issue
- 620
- Pages
- eabj7790-eabj7790
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC11000440
- OpenAlex
- W3205438960
- Cited by
- 237
- References
- 104
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 58 · 2023: 63 · 2022: 58 · 2021: 2
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science Translational Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- Funders
- National Institutes of Health
- National Cancer Institute (P30CA008748)
- National Institute of Allergy and Infectious Diseases (ZIAAI001271)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
- Keywords
- COVID-19 pandemic, SARS-CoV-2, fatal COVID-19, lung pathology, alveolar epithelial cell injury, endothelial injury, tissue repair, fibrinolysis, plasminogen activator inhibitor-1, cellular senescence, p21, SIRT1, diffuse alveolar damage, pulmonary thrombosis, lung remodeling, surfactant proteins, alveolar-capillary barrier
- MeSH terms
- COVID-19, SARS-CoV-2, Fibrinolysis, Humans, Lung, Cellular Senescence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review